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 Abstract 
The integration of scientific knowledge with health-enabling technologies (medical 
innovations) has been identified as a key policy challenge; there is a perception that the pace of 
medical innovation has lagged advances in basic research in the life sciences.  This problem has 
been framed as one of translation: the application of knowledge at the “bench” to the 
“bedside”. We propose that the lab and the clinic represent fundamentally different research 
paradigms, and that research conducted by physicians remains a central paradigm in medical 
discovery.  We analyze patent and licensing data from two prominent academic Medical Centers 
over a 30 year period.  Our findings show a strong “MD effect”: inventions by teams composed 
solely of MDs and teams with MDs MDs as team leaders are more likely to be licensed than 
inventions by teams composed of or led by PhD researchers. Inventions by teams that combine 
MDs and PhDs are not more likely to be licensed, calling into question the translational model of 
combining expertise to bridge different domains. These results are robust to a number of controls 
that account for the technological and scientific orientation of the research project and the 
investigators.  Our results help inform policy about the relationship between basic and applied 
research in medical innovation.  Our paper adds to the small body of studies that show that 
clinical research continues to play a critical role in medical innovation, even in an era of 
burgeoning molecular science and increasingly data-driven methods in the life sciences. 
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1. Introduction 
  Since the 1970s, a major shift has occurred in medical research.  The period has 
witnessed a rapid expansion of fundamental knowledge about the genome; a sharp increase in 
digital information processing and analytics; and the development of highly efficient tools, 
technologies, and diagnostics.  Teams, rather than individual investigators, have become more 
important in the discovery process, reflecting both the rise of “big data” and new high-
throughput analytical techniques in the life sciences, as well as increased specialization as the 
sheer volume of scientific knowledge has expanded (Collins, 2010; Wuchty et al, 2007).  As 
expressed by NIH director Francis Collins, “the power of the molecular approach to health and 
disease has steadily gained momentum over the past several decades and is now poised to 
catalyze a revolution in medicine . . . The foundation of success in biomedical research has 
always been, and no doubt will continue to be, the creative insights of individual investigators. 
But increasingly those investigators are working in teams, accelerated by interdisciplinary 
approaches and empowered by open access to tools, databases, and technologies” (Collins, 
2010).    
This new era in medical research has centered on molecular-level research and data-
driven discovery that has promised to yield a wave of new health-enabling technologies and 
treatments.  However, there is a widely-shared perception that scientific advances in the life 
sciences have not been matched by a corresponding increase in the rate of medical innovation: 
that discoveries made at the “bench” have not been effectively translated into useful applications 
at the “bedside” (Collins, 2011).   The lack of progress has been diagnosed, in part, as a problem 
of translation: a lag between advances in basic science and analytical techniques and their 
impact on new products (Contopoulos-Ioannidis et al, 2008; Morris et al., 2011). In this 
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interpretation, the integration of these complex domains of knowledge has been identified as a 
central policy objective, so that the expected benefits of basic science can flow to the clinic 
(Cockburn, 2006).   “Translational research” policies to improve the flow of scientific 
knowledge to clinical applications have become an important centerpiece of medical policy in 
Europe and the United States.   
The NIH defines the job of translational scientists as “taking basic discoveries about the 
causes of a disease and transforming this knowledge into a new treatment and demonstrating that 
it tangibly improves human health”1.  In 2005, the NIH issued its Roadmap for the future, with 
stronger integration of basic and clinical sciences at its core; in 2011, it founded the National 
Center for Advancing Translational Sciences (NCATS) to implement this vision.  The first new 
Center at the NIH in many decades, it attests to the importance of the translational model in bio-
medical research policy.  Several European policy initiatives similarly seek to foster integration 
of basic science with clinical applications through translational research.     
It is worth noting that the translational model of medical innovation is not rooted in 
historical linkages between science and medicine:  the application of scientific methods to 
medical innovation is relatively recent, and the hospital, not the laboratory, was the primary 
source of discovery for most of medical history.  Even before the development of a formal 
medical profession, hospitals provided physicians with “buildings and bodies” – opportunities to 
not only observe and treat the sick, but to dissect and learn from the dead (Bynum, 1994; Weiner 
and Sauter, 2003).  The introduction of modern scientific methods to medical research can be 
traced to Paris hospitals in the 19th century under the guidance of the great experimental 
                                                          
1 http://www.ncats.nih.gov/about/about.html. Translational research may also have a public health aspect, when 
framed as a process of diffusion and uptake of evidence-based medical knowledge in clinical care (Woolf, 2008).  
We refer to translational research in the first sense: the application of basic scientific knowledge to the 
development of health-enabling technologies and treatments. 
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physician Claude Bernard, whose dictum to “go first to the hospital” reflected his belief that the 
laboratory was the handmaiden to the clinic in medical discovery.   
The clinical research paradigm formed the centerpiece of medical policy in the post-
World War II period, particularly in the United States (for a review of the history, see Gittelman, 
2015), a period in which clinicians working in Academic Medical Centers played a dominant 
role in spearheading research and medical innovation (e.g. Ahrens, 1992; Gelijns et al, 1998; 
Rees, 2002; Swazey and Fox, 2004).   This period has been called the “Golden Age of Clinical 
Research” because of the unprecedented wave of treatments and health-enabling technologies 
that were developed by scientists working in clinical research settings (Ahrens, 1992; Mitra, 
2009, Swazey and Fox, 2004)2.  
In addition to the discovery of new treatments, clinical research was important in 
generating fundamental insights in biology (LeFanu, 2012; Mitra, 2009; Swazey and Fox, 2004).    
Among the most notable example was Oswald Avery’s discovery of DNA, made while working 
with a team of clinicians at Rockefeller Hospital to develop a cure for pneumonia. In their 
detailed history of the oncogene paradigm – the linking of genetics to cancer – Keating and 
Cambrosio (2001) show that the new genomics paradigm emerged from the work of clinicians 
whose unique access to human subjects enabled them to make the bridge between biological and 
medical knowledge.  
                                                          
2 Mitra (2009) details the unprecedented wave of drugs and other innovations discovered in clinical settings in the 
post-war period: penicillin and other antibiotics; streptomycin for tuberculosis; cortisone for immune system 
disorders; chlorpromazine, which changed understanding and treatment of psychiatric disorders and laid the basis 
for modern psychiatry; chemotherapy drugs; immune-suppressants for organ transplantation; polio vaccine; and 
contraceptive medications.  Treatments and devices included cardio-pulmonary bypass and open heart surgery, 
cardiac catheterization, organ transplantation, joint replacement, renal dialysis, intra-ocular lens implant, cochlear 
implant, in vitro fertilization; the invention of the ventilator and intensive care of infants; the operating microscope, 
fiber-optic endoscope, cardiac pacemaker, laser, ultrasound, isotope scan, CT, MRI, and PET scans, and the linear 
accelerator. 
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We argue that the bedside to bench model of medical innovation remains an important 
discovery path in medical discovery, even in a period of rapid advances in the biological 
sciences.  Our claim is a challenge to the perspective that the declining rate of medical 
innovation can be diagnosed as insufficient application of basic science to medical knowledge.  
We propose that doctors working in hospitals remain central to medical innovation because they 
have unique opportunities for insights that emerge from the joint activities of research combined 
with interactions with living patients.  We compare the research paradigms of clinicians working 
with observational data of patients with that of basic scientists who work with data at the intra-
cellular and molecular level, and propose that the clinical research paradigm is uniquely adapted 
to medical innovation.  A startling extension of this claim is that the decline in the rate of 
technological progress in medicine (particularly in drug discovery) as compared to prior periods 
is not due to too little basic science, but to prioritizing basic science, big data, large teams, and 
high-throughput analytical techniques over clinical methods in medical innovation.  
 The role of the clinic in medical policy has been a central topic in the medical policy 
literature (e.g. Gelijns et al, 1998; LeFanu, 2012, Mitra, 2009; Rees, 2002; Scannell et al, 2012; 
Williams, 2005) as well as the literature on the economics of technology (Gittelman, 2015; 
Hopkins et al, 2007; Nelson et al, 2011; Nightingale, 1998; Nightingale, 2004).   Our study is 
among the first to empirically identify the relative contributions of clinical and basic research to 
medical innovation. By identifying the training of scientists as well as their scientific specialties, 
our analysis helps tease out the impact of distinct research paradigms from the skills and 
specialized knowledge that different team members bring to the project.  
 The context we study is Academic Medical Centers (AMCs).  These organizations, 
which emerged in the research landscape in the mid-20th century, bring together clinicians, basic 
scientists, patients, support staff, and state of the art technologies and laboratory facilities in an 
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institutional setting that is devoted simultaneously to medical practice and rigorous scientific 
research. They allow for inter-disciplinary collaborations in an environment that cannot be 
duplicated in university departments or private R&D labs (Bercovitz and Feldman, 2011; 
Nathan, 2002; Rosenberg, 2009). Discoveries with commercial potential are frequently patented 
and licensed to firms for further commercial development.  Academic Medical Centers thus 
provide a fruitful context in which to study the contributions of basic and clinical research to 
medical innovations.   
Our analysis is focused on two world-class AMCs: the Mass General Hospital and 
Brigham Women’s Hospital, both affiliated with Harvard Medical School. These have been the 
sites of important health-enabling inventions, including the first organ transplant and limb 
reattachment, diagnostic tests, numerous new drugs, and cosmetic lasers. We analyze licensing to 
firms as an indicator of an invention’s commercial potential.  While not all licensed inventions 
eventually become products, a license is an indicator of commercial value that is not captured in 
patent or bibliometric data.  We analyze the probability of a patent being licensed as a function 
of the research background of its inventors, as indicated by their training as clinicians (Medical 
Doctors, MDs), basic scientists (Doctor of Philosophy, PhDs), or a combination (MD-PhDs).  
While prior work has studied the role of patenting and publishing on scientists’ contribution to 
innovation in biomedicine (e.g., Subramanian et al, 2013, Baba et al, 2009), and the 
characteristics of inventing teams on innovation outcomes (e.g., Bercovitz and Feldman, 2008; 
Bercovitz and Feldman, 2011), ours is the first to identify training in clinical and basic research 
as a key variable predicting the market performance of inventions.    
Our study covers a time period from the late 1970s to the mid-2000s when molecular 
biology, genetics, and large-scale analytical methods took increasing importance in bio-medical 
research at AMCs, and indeed our data reflect such a rise.   We leverage the composition of 
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inventive teams to study whether the training of researchers affects the probability of a license, 
conditional on a patent being issued. We find a strong “clinician effect”: the presence of an MD 
or MD-PhD on an invention significantly increases the chance of its being licensed, whereas 
inventions by PhD scientists are less likely to be licensed.  The only time that PhD scientists 
have a positive effect on licensing is when the scientist is also a clinician (MD-PhD).  We control 
for a number of technological, field-specific, organizational and individual factors that might 
influence the distribution of research domains as well as the commercial success of patents; our 
results are robust across a range of such controls.  The results suggest that clinical research 
remains an important paradigm in medical innovation, even in an era in which basic research, 
cross-disciplinary teams, big data, and large-scale analytical techniques have become central in 
medical research.   
2. Basic and applied research in technological innovation 
Basic research and technological innovation can usefully be understood as two distinct 
paradigms of learning characterized by different sets of practices and search routines3.  These 
differences have been explored in the context of communication and codification practices; 
methods of validation and experimental conditions; decision-making processes; and the extrinsic 
and intrinsic motivations of investigators (Aghion et al, 2008; Allen 1984; Nelson 2003; 
Nightingale, 1998; Rosenberg, 1990; Sauermann and Roach, 2014).  Broadly, basic research can 
be characterized as aimed at uncovering cause-effect relationships to produce knowledge that 
facilitates understanding of natural phenomena.  To accomplish this, basic science reduces 
phenomena to their essential states, constructing experimental settings that are abstractions of the 
complexity that characterizes most phenomena as they exist in nature. Learning proceeds with 
                                                          
3 Gittelman (2015) in this Special Issue contains a longer discussion of research paradigms and application to 
medical research. 
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predictive models, validation of prior theories, and “offline” experimentation that simulates, 
rather than replicates, real-world phenomena (Nelson, 2003).  
Technological innovation, on the other hand, is concerned with producing artefacts that 
must function reliably across a variety of unpredictable real-world contexts.  Problem solving 
therefore focuses on uncovering robust design principles rather than validating theory.  
Experimentation involves objects that closely resemble their real-world analogs, and feedback-
based, experiential learning provides clues to mechanistic solutions that work in variable states 
of nature.  Fundamental understanding may occur as a by-product of technological search, but is 
not a central object of learning; indeed, causal understanding of a problem is frequently 
unhelpful in finding technological solutions (Vincenti, 1990).   
In sum, search in basic science seeks to reduce natural complexity in order to develop and 
test universal cause-effect relationships.  Technological learning studies phenomena in their full 
complexity to uncover understandings of functional, rather than causal, relationships to design 
artefacts that function well in variable states of nature. Because of different orientations towards 
the production of knowledge and the production of artefacts, early writers emphasized that 
interactions between basic science and technological innovation are episodic and sporadic in 
nature, rather than a smoothly occurring transfer (Allen, 1984, De Solla Price, 1965; Mansfield 
and Lee, 1996).   
Nelson (2003) proposes that while learning-in-practice (“techno”) and fundamental 
understanding (“logy”) co-evolve, the most valuable scientific fields for technological innovation 
are the applied sciences whose methods and objectives study complex phenomena as they exist 
in nature, and thus more closely resemble technological learning than they do basic science. Thus 
the specialized practices of scientific fields is a key variable in theorizing the ways in which 
science usefully engages with technology,, in particular, the degree to which researchers study 
8 
 
complex phenomena in their natural states (or close analogs thereof) or rely on predictive theory 
and abstract models..   
3.   Basic and clinical research in medical innovation 
  Apart from case histories, there is scant statistical evidence of the relative contribution of 
these paradigms to the productivity of medical innovation.  Partly, this reflects the great 
difficulty in tracing the origins of an innovation that may have taken decades to develop into a 
treatment.   Gelijns et al. (1998) study blockbuster drugs as well as two major devices in 1993 
and find that secondary uses – a major source of medical innovation - had been discovered for 
nearly all of them, and that these secondary uses accounted for nearly half of sales within two 
years.  These new discoveries were made both at the bench as well as the bedside, and illustrate 
the importance of clinical data as a starting point in triggering new medical discoveries.  A recent 
study examined the sources of discovery of new off-label uses for drugs, and found that 59% of 
the innovations came from clinicians practicing in the field rather than from drug companies (De 
Monaco et al, 2006).     
Recent empirical investigations of the biopharmaceutical industry – which relies heavily 
on science for innovation – suggest patterns that are consistent with the proposition that applied 
science contributes more to private-sector innovation than basic science.  However the evidence 
remains indirect.  Several studies have found a negative relationship between highly cited 
scientists (or highly cited papers) and valuable patents (Gittelman and Kogut, 2003, Rothermel 
and Hess, 2007, Subraminan et al, 2013).  Instead, a number of studies [Gittelman and Kogut, 
(2003), Subramanian et al (2013), Baba et al (2009), Rothermel and Hess (2007)] find that 
boundary spanning scientists who engage in both scientific and technological activity make a 
greater contribution to innovation than scientific “stars”, suggesting that individuals who span 
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the worlds of research and technology are more valuable to firms than those who specialize in 
research.   
Even though these studies have typically been restricted to a single field, they do not 
account for the training of the scientists.   As a result, it is difficult to ascertain from these 
findings whether the boundary spanners are applied scientists or are basic scientists engaged in 
translation to a market.  They provide indirect evidence that applied research is more useful than 
basic research for innovation, since it is plausible that scientific “stars” are more likely to be 
basic researchers: journals in applied sciences tend to be less prestigious and receive fewer 
citations than basic science journals, and paper-based citation trails in applied disciplines are 
shorter than in the basic sciences (De Solla Price, 1970).   However, while studies are suggestive 
of a negative (positive) effect of basic (applied) science on successful innovation, the evidence is 
indirect and the question remains open regarding which types of scientific research are 
associated with successful invention.   
Much of the theoretical literature seeking to understand the contributions of basic and 
applied research to discovery focuses on the level of uncertainty of the problems being solved, or 
the “upstream” versus “downstream” nature of problem solving (e.g., Aghion et al, 2008).  While 
helpful in understanding how incentives in firms and universities can lead to an efficient division 
of innovative labor, variation in the uncertainty of problems is less useful for understanding the 
contributions of basic and clinical research to medical innovation: we propose that it is not the 
level of uncertainty of problems that matters for performance, but the idea that each group 
confronts complexity in a different manner4.   
                                                          
4 Moreover, the utility of categories such as “upstream” and “downstream” inventions is limited in the case of 
medical innovation, where scientific insights can have immediate utility.  For instance molecular probes, 
diagnostics, devices, and new drug compounds may all emerge from basic science.  A PhD scientist patented an 
“inexpensive, readily manufacturable” device that detects apnea by measuring the amount of CO2 in a person’s 
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Both basic and clinical scientists working in academic hospitals study complex problems 
and use clinical data in their work.   We propose that clinical research adheres to a logic of 
discovery that hinges on a unique combination of medical education, interactions with living 
patients, and research.  The phrase “living patients” is important, since PhD scientists also utilize 
clinical data; however, their disease models and data abstract from the context of the full 
organism, while clinicians, in contrast, work with “naturally-occurring disease models”, e.g. 
pathological states as expressed in the human body, and utilize data from observations of living 
subjects (Crowley and Thier, 2001). 
Clinical and basic researchers inhabit different epistemic cultures that privilege distinct 
and sometimes conflicting priorities: data versus cases; models versus observation; theories 
versus induction; genes over patients.   Dougherty and Dunne’s (2011) ethnographic research 
uncovers a sharp contrast between two groups of scientists, whom they refer to as “digital” and 
“therapy” scientists.  These groups correspond to those working in the basic and clinical 
paradigms, respectively.  Digital scientists frame problems and products using abstract, 
systematic maps of the search space, based on identifying and following “knowns”, e.g. gene 
maps to identify well-specified targets.  Therapy scientists work differently: they focus on local 
search of “unknowns”, studying concrete, emergent processes.  They are more involved in 
physical interaction with tangible materials and study the body’s functioning in real-world 
contexts.    
The central role of clinical research in solving medical problems hinges on the idea that 
developing solutions for complex medical problems does not commonly originate in the 
laboratory: the immense complexity of biological systems interacting with a variable 
                                                          
breath (patent number 4,648,396).  Indeed, inventions involving human subjects frequently face high regulatory, 
testing and bureaucratic hurdle before they may be considered proof of concept, and thus may be more “upstream” 
than those that emanate from a laboratory.   
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environment, coupled with the relative gaps in scientific understandings of biological processes, 
means that predictive, abstract models are limited in their utility.  Instead, close observation and 
study of humans by physicians trained in research is a useful starting point for discovery.   
Clinical researchers spend several years studying medicine, physiology, and pathology, and their 
practice involves ongoing interactions with afflicted human subjects. They therefore have the 
opportunity to observe complex physiological phenomena as they exist in various states of 
nature.    Basic scientists receive deep scientific training but do not engage in interaction with 
living patients as part of their professional practice.  They are specialized in studying biological 
sub-systems at a more fundamental and specialized level than is presented in complex biological 
systems, e.g. intra-cellular or molecular structures and processes.    Both groups study complex 
processes, but only clinicians study complexity as it exists in nature.  By adopting a focused, 
reductionist approach, basic researcher have fewer opportunities than their clinical counterparts 
to make valuable connections between the lab and clinical observation.  We propose that this 
difference will be expressed in the success of the inventions of these two groups.  
To illustrate this difference in search logics, we contrast inventions by two 
anesthesiologist specialists in our dataset.  A novel painkiller was patented by Dr David Borsook, 
an MD-PhD who works extensively with patients suffering from neurological pain.  Dr. 
Borsook’s laboratory research involves using advanced imaging technologies to develop clinical, 
observational measures of patients suffering from disease-related pain.  He was involved in a 
clinical trial testing a cancer drug, and noticed that administering the drug to patients decreased 
their pain.  According to the description in the patent (5905069)5, “The invention is based on the 
unexpected discovery that administration of a spicamycin derivative to a patient suffering from 
                                                          
5Borsook, D. and J.W. Clark, “Methods of decreasing or preventing pain using spicamycin or derivatives 
thereof”, U.S. Patent 5905069, filed January 26, 1998 and issued May 18, 1999 
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pain resulted in a significant decrease of that pain”.  Borsook’s inventions was possible because 
he was able to observe the operation of the drug in the human body and theorize why it worked, 
leading to his subsequent invention. 
His work differs markedly from Dr. Charles Serhan, PhD, who has several patents for 
anti-inflammatory drug compounds.  Dr. Serhan's research focuses on “the cellular and 
molecular mechanism(s) that govern endogenous anti-inflammation and resolution mechanisms 
in inflammation.Dr. Serhan's approach in elucidating the molecular map or resolution circuitry 
involves a multidisciplinary systems biology approach employing lipid mediator informatics, 
cellular and molecular analyses integrated in a systems approach to elucidate critical biochemical 
pathways in the resolution response in vivo.6”  Both researchers employ clinical data in their 
work: however, Borsooks research hinges on observations of intact patients using new imaging 
technologies, while Serhan’s methods rely on large-scale analysis of intra-cellular and molecular 
data.   
In sum, we propose that iterations between observation and study of patients with 
research provides valuable opportunities to make connections about treatments that are not 
available to scientists specializing in research only.   We therefore expect that the inventions of 
clinical researchers will be more likely to be valued in a market than inventions of basic 
researchers, and that this difference is not attributable to the level of uncertainty, field 
specializations, or closeness to the final market of the inventions.   
While we expect that the clinical paradigm provides unique opportunities for medical 
discovery, teams that combine the clinical, patient-oriented perspective with expertise in basic 
science could have fruitful opportunities for diverse knowledge sharing, creativity and discovery 
                                                          
6 http://research.bwhanesthesia.org/research-groups/cetri/serhan-lab accessed October 19, 2015 
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Moreover, the analytical models and data-analytic approach of basic life scientists can augment 
and complement the “small-n” observational studies of clinicians.   Indeed, cross-disciplinary 
teams that combine clinical and basic science are at the core of translational medicine. The 
translational model hinges on the idea that combinations of clinical and basic researchers on 
teams will increase the inventive performance as compared to teams comprised of one or the 
other paradigm.   
However, our assertion that these groups adhere to different logics of discovery mean that 
combining them on teams does not “solve” the problem of medical innovation: teams are not 
merely the sum of the knowledge of their individual members.  We theorize that even when 
teams combine clinicians and basic researchers, team leaders will be important in setting in 
motion the intellectual paradigm of the project as a whole, clinical or basic research, which will 
shape the problem-solving approach and opportunities for creative discovery.  Therefore, we 
expect that the research training of the team leader will be predictive of its commercial potential, 
and that, following on the above discussion, inventions that are led by clinicians are more likely 
to succeed than inventions where the project is led by a basic researcher, even if the team 
combines both types of researchers.   
4. Empirical context 
a. Academic Medical Centers: The Mass General  and Brigham Women’s Hospitals  
Modern academic medical centers were designed to combine state-of-the art medical 
technologies and lab facilities, offering researchers the opportunity to engage in trans-
disciplinary research motivated by practical problems.   These individuals were conceived as key 
agents in the integration of laboratory science with clinical applications and were the main 
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beneficiaries of NIH policies to increase grant funding of biomedical research in universities 
(Nathan, 2002).   
At the institutional core of the Academic Medical Center is the physician-scientist, 
“individuals with an MD degree who are engaged in research as their primary professional 
activity” (Ley and Rosenberg, 2005).  The institutionalization of physician-scientist career track 
was an American innovation of the early 20th century when medical schools, which had been 
practice-based, for-profit institutions, were joined with research universities under the guidelines 
of the Flexner report.  The Flexnerian goal, enshrined in the “Full time plan”, was to create a 
career path in academic hospitals that allowed physicians to devote themselves to research on an 
equal footing with university faculty, freed from the financial need to practice private medicine 
(Bryan and Stinson, 2002).  These individuals were conceived as key agents in the integration of 
laboratory science with clinical applications and were the main beneficiaries of NIH policies to 
increase grant funding of biomedical research in universities (Nathan, 2002).  Generally, clinical 
researchers only have MDs, but increasingly they also have PhD degrees; and by the mid-2000s 
the number of MD-PhDs applying for NIH research grants was almost equal to the number of 
MD-only applicants (Ley and Rosenberg, 2005). 
 
Our study focuses on the Massachusetts General Hospital (MGH) and Brigham and 
Women’s Hospital (BWH). In 1994, these two AMCs became the founding members of Partners 
HealthCare, the largest healthcare provider in Massachusetts. In terms of quantity of NIH 
funding, MGH consistently ranks first and BWH second among all hospitals. 7 In 2014, the two 
hospitals had a combined research revenue of over $1.4 billion.8 Both of these Academic 
                                                          
7 http://www.report.nih.gov/award/index.cfm accessed November 30 , 2015 
8 Partners HealthCare Research Management, Annual Report 2012. 
http://navigator.partners.org/ResearchSupportOffices/Research-Management-Annual-Report-FY12.pdf accessed 
April 11, 2014 
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Medical Centers are Harvard teaching hospitals, and are ranked among the top 10 hospitals by 
US News and World Report in 2013.   
Both institutions have been at the forefront of academic research and clinical innovation 
worldwide.  MGH, founded in 1811 as the third US hospital, has been the site of the first 
demonstration of the use of ether for surgical procedures in 1846, the identification of 
appendicitis in 1886 and the first severed limb reattachment in 1962.  Similarly, in 1923, the first 
heart valve surgery in the world was conducted at Peter Bent Brigham hospital, predecessor to 
Brigham and Women’s hospital. The same hospital was also the site of the world’s first organ 
(kidney) transplant in 1954.    
 Both have been at the forefront of basic research in the life sciences.  MGH’s molecular 
biology department was founded in 1982 with a grant of $70 million by Hoechst, and it is the 
home institution of Nobel Prize winner Jack Szostack, who created the first artificial 
chromosome (Culliton, 1982). Innovative products that were invented at these two institutions 
include the drugs Enbrel, Liraglutide, Pepcid, Sensipar and nitric oxide for use in the treatment 
of newborns in respiratory distress; diagnostic tests and devices including tests for Alzheimer´s, 
pre-eclampsia; vitamin-E infused polyethylene prosthetics for knee and hip replacements, Fraxel 
lasers for skin rejuvenation as well as numerous research tools, genes and genetically modified 
organisms. Inventions like these that are patented have generated approximately $110 million in 
licensing income in 2012 (RVL Annual Reports, various years).9 
b.  Basic and clinical scientists in AMCS 
There are three main types of scientists working in Academic Medical Centers: MD, MD-
PhD, and PhD.   In the United States, MD (“Medical Doctor”) degrees are awarded by medical 
                                                          
9 Partners Research Ventures and Licensing (RVL) Annual Reports for years 2005-2012 
http://innovation.partners.org/resource_center/annual_reports, accessed April 1, 2014 
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schools that require four years of training, and graduates must complete and additional three to 
eight years of work in a hospital in their specialty as a physician-apprentice (resident).  Medical 
schools are practice-oriented and students learn biological science but do not receive training in 
research methods.  For a variety of reasons, the majority of MDs do not elect for careers in 
research: the number of physicians whose primary activity was research declined from about 5 
per cent of all physicians in the early 1980s to less than 2 per cent in the mid-1990s (Ley and 
Rosenberg, 2005).  MD-PhDs are clinicians who have opted for additional training, in the form 
of a PhD, to develop research expertise within a field of specialty.  The MD-PhD degree was 
created and funded by the NIH to address the gap in research training at medical schools, and 
was intended to encourage physicians to engage in research careers.  PhD scientists work in non-
clinical specialties; though they may encompass fields of biology (e.g.  biochemistry) they do not 
involve patient care, and students receive greater training in research methodology, statistical 
methods, and basic science.   The emergence of fields such as genomics, proteomics, and large-
scale analysis of genetic data have increased the role of PhD scientists in bio-medical research.    
We associate MDs with clinical research and PhDs with basic research.  While they may 
work on similar types of problems or diseases, e.g. oncology, pharmacology, hematology, their 
training differs sufficiently to warrant the distinction in the work that they do: MDs are trained in 
medicine and related fields, and have experience in patient-oriented research, while PhDs are 
formally trained in fundamental disciplines and sophisticated analytical techniques in such fields 
as molecular biology, genetics, biochemistry, and bio-statistics. We interpret MD-PhDs as 
clinicians who also have deep knowledge of a research specialty.   
c. Licensing  
The importance of licensing technology, particularly from academic institutions, has been 
expanding in recent years. Arora and Gambardella (2010) review data from various sources to 
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arrive at a size of approximately $100 billion in 2002 for the global market in technology, about 
double their earlier estimate of $35-50 billion in the mid-1990s. (Arora et al. 2001; Arora and 
Gambardella, 2010, cf. Athreye and Cantwell, 2007; Robbins, 2006). Other survey based studies 
point to the increasing importance and rate of out and in-licensing by firms (Sheehan et al, 2004; 
Zuniga and Guellec, 2008; Tsai and Wang, 2009). 
Licensing markets are particularly important in bio-medical fields, where many early-stage 
discoveries originate in university setti 
ngs, and medical schools are particularly central  in university licensing (Bercovitz and 
Feldman, 2008; Mowery and Ziedonis, 2002).  During the 1980s, universities became 
increasingly aware of the commercial potential of their faculty’s research and disclosure became 
a normal faculty practice (Bercovitz and Feldman, 2008; Sampat, 2006).  At the same time, 
private firms in bio-medicine shifted towards more out-sourcing of research, leading to active 
vertical markets for technology involving universities, medical schools, biotechnology firms and 
large pharmaceutical firms (Stuart, Ozdemir and Ding, 2007).  In a survey of firms using 
university technology, Thursby and Thursby (2004) find that more than half of the respondents 
use university technology in new product development and 23% note that in-licensed patents 
from universities were crucial in the development of their products.   
5.  Sample, Variables and Methods   
Our objective is to analyze the relative contributions of clinical and basic research to the 
commercial potential of an invention.  Our data consists of patented inventions, and we focus on 
licensing of those inventions to firms as a measure of commercial potential.  It is an imperfect 
proxy. It does not indicate whether a product emerged from the license; however, it does indicate 
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that a firm perceived a potential for commercialization and was willing to pay in order to develop 
the technology further.   
Data was collected on all patents issued to the two AMCs between 1977 and 2007, along 
with their associated licenses.10 Multiple patents are sometimes issued for a single invention, 
called a case. Patents from the same case are almost invariably licensed together as a portfolio, 
have the same inventors and come from the same parent patent application through patent 
divisions, continuations and continuations-in-part. To avoid bias created by including related 
patents in our estimations that are identical to others in the same case for many key variables, our 
unit of analysis is the case, rather than the individual patent.  
We do not include all inventions in our sample.  We exclude co-assigned cases in which 
the invention was assigned to multiple institutions such as other firms or non-profit 
organizations.11  We also exclude inventions that are the result of company sponsored research 
agreements (SRAs). Such inventions are likely to reflect the research agendas of the sponsor 
rather than the independent research of the scientists.   While interesting in its own right, this 
could bias our results, as the company interests, rather than the scientists alone, would impact the 
selection of research question, the team, and the research agenda.  Furthermore, patents from 
                                                          
10 We collect the data from the Technology Licensing Office in charge of the intellectual property at the 
two academic medical centers. Faculty members at the AMCs are required to submit an invention disclosure to the 
TLO if they believe they have conceived of an idea that is novel and has a potential for commercialization. After 
extensive review regarding the patentability of this invention a decision is made by the TLO about whether to file an 
application for one or more patents. Once a patent is filed, the TLO actively researches potential licensees for the 
invention; inventors may also initiate contacts. In cases of company-sponsored research, the sponsoring firm usually 
has an automatic right of first refusal to any inventions emanating from the research.   
11 Under US patent law, co-assignees are allowed to use or license the invention to others without consulting each 
other.  Since we only observe licensees to the MGH or BWH, we cannot be sure that we are capturing all licenses to 
co-assigned patents.  Information about the institutional assignment of patents comes from the patent front page. We 
check assignments against USPTO assignments website, which is more complete (and correct) than the front page of 
the patent. 
19 
 
sponsored research are almost always automatically licensed to the sponsoring firm, or grant the 
right of first refusal to the sponsor.    
In total there are 495 inventions, where each observation represents a case in which at 
least one patent has been granted between 1977 and 2007, and for which the hospitals are the 
sole patent assignees12.  Of those inventions, 382 have only one patent associated with them, 
while the remaining 113 have multiple patents associated with the same case.   
a. Dependent variable: Licensing  
We use the date of the earliest license to measure the licensing event, which we interpret 
as evidence of an attempt to commercialize or use by a firm. Patents may be licensed multiple 
times; some are licensed through non-exclusive agreements, some are sublicensed by the first 
licensor. Additionally, licenses may be terminated and the invention then can be relicensed to a 
different entity.  Our estimations do not include these complex transactions but only focus on 
whether an invention was ever licensed to any firm, conditional on a set of explanatory variables. 
Our data is right censored; inventions continue to be at risk of licensing after our study 
period expires.  Moreover, inventions both enter and exit the risk set over time as they are newly 
patented (entry) or licensed, abandoned or expire (exit)13.   Because we have right censored data 
                                                          
12 Some prior research has used invention disclosures as the level of observation, including invention disclosures 
that have not been patented (Kotha et.al, 2013).  We do not include them because in our case they automatically 
remain unlicensed.  Public disclosure of the unpatented inventions is certain and fast since they are emanating from 
academic institutions where secrecy is not a preferred form of intellectual property protection and where 
dissemination of ideas and publication of results is the currency of career advancement. Furthermore by focusing on 
patented invention disclosures we ensure that all inventions in our sample have passed a threshold for patentability, 
based on the USPTO requirements.  Inventors themselves are academics who often will file their latest paper as an 
invention disclosure and are generally less equipped than TLO officers and patent attorneys to be unbiased judges of 
the patentability or commercial potential of their own research.  
13 Abandonment of a patent occurs if the TLO decides, post-grant, that it is no longer desirable to pay the 
maintenance fees to keep a patent in force.  These decisions may be made at 3.5, 7.5 and 11.5 years after the patent 
has been granted.  Abandonment is equivalent to expiration, as an abandoned patent is not available for licensing. In 
cases where we have multiple patents per case, the case is at risk for licensing until the last patent is abandoned or 
has expired. We gather abandonment information from the USPTO supplemented with IP Thompson’s Delphion 
information on patents in force.  
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with exit and entry over time, we employ a survival model that measures time to first license; the 
Cox Hazard model estimates the hazard of licensing by combining information about entry and 
exit of inventions with information about whether the exit was associated with licensing.  An 
invention disclosure enters the risk set beginning at the priority (or provisional filing date) of the 
first filed patent.  We exclude an invention from the risk set after the first license. 
b. Explanatory variables 
To capture the effect of different research paradigms on inventions, we identify the 
degrees of each inventor listed on all patents within each case.  An inventor on a patent, by law, 
must have contributed “to the conception of the invention” i.e. to at least one of the claims of the 
patent. We are therefore confident that we are capturing individuals who made a meaningful 
contribution of their knowledge to the invention.  
We use a variety of sources to identify inventors’ degrees as either MD, MD-PhD, or 
PhD.   The main source is the invention disclosure itself.   Each degree is further checked against 
a variety of other sources14. Inventors that had only a Master’s degree or a Bachelor’s degree are 
classified as “other”.  
Lead inventor degree – We expect that the research paradigm of an invention will be 
reflected in the degree of the lead inventor on the invention (Bercovitz and Feldman, 2011).  We 
use the first listed inventor on the inventor disclosure form (labelled “Lead Inventor”) who is 
generally (though not always) also the Primary Investigator of the project.   Therefore, we 
interpret the degree of the lead inventor as defining the paradigm of the research that initiated 
                                                          
14 These include internal directories, ProQuest Dissertations and Theses Database, CVs and university biography 
webpages.  Published articles were also used to identify a researcher’s degree.  Where possible, graduation dates 
were identified; in a few cases there were people in an MD or a PhD program at the time of patent filing – they were 
considered MDs or PhDs respectively. 
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and guided the invention.  We create a series of dummy variables that indicate the educational 
degree of the lead inventor, again using the categories MD, PhD and MD-PhD.   
Figure 1 shows the number of cases in our dataset by the degree of the lead scientist.15  
The graph shows that inventions for which the Lead Inventor had a PhD rose steadily since the 
early 1990s, while inventions led by MDs declined in the late 1990s. However, the number of 
inventions with Lead Inventors with MD-PhDs grew in the late 1990s, which likely reflects 
changes in the degree composition of physician-researchers over this period, reflecting a trend in 
which junior clinical investigators seeking a career in research (versus practice only) are more 
likely to pursue an MD-PhD than in the past (Ley and Rosenberg, 2005).  Overall, the data show 
                                                          
15 13 teams whose first inventors are coded as “Other” or are not available are excluded from the graphic. 
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the strong increase in PhD scientists’ contributions to invention in the late 1990s, likely 
propelled by the rise of molecular biology,genetics and other basic fields in medical research.  
Invention team type– Inventions can include MDs, PhDs, MD-PhDs as inventors, in a variety of 
combinations.  We measure this in two main ways16:  
Single Domain inventions consist of those in which all scientists share the same degree, and can 
be either Single Domain Clinical (all MDs) or  Single Domain Research (all PhDs). The presence 
of an MD-PhD on a case automatically disqualifies it from either category.  
Cross-Domain  Inventions combine clinical and PhD scientists.  This can happen in two ways.  If 
an invention includes different individuals who are MDs and PhDs, the invention is called Cross 
Domain Distributed.  If an invention includes at least one MD-PhD, plus any other combination 
of degrees, we label it Cross Domain Integrated because at least one team member spans both 
disciplines.  
  About 30% of cases have only one inventor; these are categorized using the above 
criteria.  Only the Cross-domain distributed category is by construction required to have more 
than one researcher.   
c. Control Variables 
Inventor characteristics 
Lead Inventor Experience - Faculty at AMCs are on an academic career track, and many 
are engaged in the discovery of inventions and collaborations with firms: there is a great deal of 
variation in the degree to which they have a “taste” for commercialization, and some are more 
                                                          
16 The inclusion of a scientist with a another degree besides MD, PhD or MD-PHD did not change the team type as 
long as there was at least one MD, MD-PhD, or PhD on the team.  However, teams that have only inventors with 
another degree are classified as “Other degree.”  Only six inventions are classified as “Other degree”. 
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inventive than others.  We want to capture the involvement of faculty in commercialization that 
is independent of their specialty, field of research, and scientific standing.  We construct a time-
varying variable that counts the number of prior patented inventions of each lead scientist up to 
the time of the current invention.    
Scientific specialization– In addition to the technological characteristics of the invention, 
we want to capture the areas of work that the scientists are engaged in.  This helps to control for 
the observation that differences in PhDs and MDs might correlate with different types of 
research specializations.  Using a variety of sources, but mainly relying on publications in the 
Web of Science, we collect data on the departmental affiliation of each inventor at the time the 
case was filed.  Departments evolve over time, and different departments often cover 
overlapping subjects.  We therefore assign keywords to these departmental affiliations that best 
capture the specialty of the department as indicated in its name, e.g. Oncology, Molecular 
biology, Pediatrics, Pathology, Surgery, Psychiatry, etc.  Each invention is coded as having a 
specialization if there is at least one inventor with that specialization on any of the patents; 
inventions may thus contain more than one specialization.  
Star Inventor   This variable captures whether any of the inventors on an invention is a 
highly-cited scientist, as listed by the Institute for Scientific Information, which identifies 
individuals whose citations place them at the pinnacle of their respective fields.  This variable 
captures the effect of scientific excellence and high-impact science on invention; while we have 
not hypothesized a specific effect, prior empirical literature as discussed above has found a 
negative effect, which we speculate may be due to the fact that highly cited scientists are more 
likely to engage in basic research.  We include it in our estimations to explore this relationship 
further.  We also create a variable that indicates if the star is also a clinical scientist. 
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Single inventor – This is a dummy variable that indicates whether the invention has only 
one inventor.  
 We also include an additional variable, “Number of inventors” to account for the 
number of unique inventors listed on the case.  
 Patent characteristics  
Technology Type – The inventions span a wide array of technologies, reflecting the 
variety of knowledge that contributes to innovation at the two AMCs.  The technology of an 
invention might impact demand for the technology and the time to licensing. For example, 
inventions might include software for an MRI machine, a new catheter or a diagnostic test for 
Alzheimers.  A medical device may be licensed more quickly than a drug molecule because it 
has a different development and clinical trial requirements affecting FDA approval timeline and 
return on investment. Similarly, a research tool such as a genetically altered mouse is likely to 
have a different licensing profile than a drug molecule.  We include time-invariant dummy 
variables to capture these effects within each of the types of technology represented by the 
inventions. 
 We use the main (first) USPTO assigned patent class to categorize each invention into 
six main groups: Drugs, Molecular biology, Surgery, Chemistry, Imaging and “other”.   We 
further divide all inventions into device and non-device inventions. We define a medical device 
as an object or apparatus that has human body contact and/or is used on the human body and 
requires an FDA approval as a medical device.  Even though there is a wide variation within 
medical devices with regard to their complexity and novelty, this classification is nevertheless 
useful as the approval process is similar for most devices, and licensing of devices might differ 
systematically from non-devices across the technology fields we identify.   
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Figure 2 examines the composition of inventions by technology over time. Overall, the 
data indicate a rise in basic research, with chemistry and molecular biology increasing; “other”, 
which in this graph includes imaging and other categories with very few cases, is also increasing.  
There has been a sharp fall in drugs, this is likely to be driven in part by an increasing shift 
toward sponsored research in drug discovery at AMCs; sponsored research inventions are 
excluded from our sample.  Surgery remains an important class of inventions throughout the 
period. 
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Figure 3 explores the distribution of technologies by the degree of lead inventor.  This is 
important for our conceptual claim that differences between inventions by clinical and basic 
researchers stem from distinct processes of discovery, not different fields of discoveries.  
Empirically, we are concerned that our statistical estimates of “Basic” and “Clinical” variables 
be independent of field effects.  If scientists self-select into certain kinds of projects, it will be 
difficult to know if the results are driven by research paradigms or unobserved variation across 
technology fields. We don’t see such a pattern in the univariate data: molecular biology, which is 
associated with basic research, has the highest concentration of leads in a single degree type - 
PhDs, however this maximum is only 55%; the remainder have a clinical degree.  Overall the 
data show that PhDs, MDs and MD-PhDs are distributed widely across technologies, such that 
these categories do not allow for a clean distinction between “basic” and “applied” fields of 
research.  This likely reflects, in part, the opportunities at Academic Medical Centers to merge 
basic and clinical research across an array of medical fields. 
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To further explore our claim that it is the logic of discovery, rather than the fields of 
inventions, that sets clinical and basic scientists apart, we look for an indication that clinical 
researchers are involving human subjects to a greater extent than PhD scientists across all their 
inventions.  We search the abstracts of all patents for clinical keywords and code whether an 
invention (which may consist of multiple patents) has a clinical keyword in its abstract.   We find 
that inventions that have a clinician as the team leader (MD or MD-PhD) are far more likely to 
include a clinical keyword than teams led by PhD scientists:  44 per cent versus 30 percent, 
respectively17.  A similar pattern is found when looking at the composition of teams: the highest 
incidence of clinical keywords is found in inventions that include an MD-PhD on the team 
(48%), followed by teams composed only of MDs (40%); teams that combine PhDs and MDs 
(31%) and teams with only PhDs (28%).  These data indicate that despite the fact that there do 
not seem to be major differences in the fields of inventions, clinicians are much more likely to 
engage in research that involves human subjects, from which we build the claim that they are 
likely to follow a different logic of discovery that is more conducive to creating commercially 
successful inventions.  
Bibliometric variables  
We include other characteristics of the patents that may correlate with the probability of 
licensing; valuable patents frequently have bibliometric characteristics that correspond to the 
effort put into the invention.  That effort, in turn, can affect the probability of licensing.  
Backwards citations are the maximum number of patents cited by any patents in a case; this 
measure correlates positively with the scope of the claims on the patent, which suggests greater 
                                                          
17 The Web of Science was used to generate a list of clinical keywords.  These were: patient; clinical; vertebrate; 
human; full living; organism; subject; protocol; consent; administer; trials; mammal; blinded.   This is an error-prone 
measure, insofar as inclusion of a clinical keyword in the abstract does not mean that humans were involved in the 
discovery.  However, this would tend to work against the large difference we already find between clinicians and 
basic researchers in use of these keywords.    
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strength of intellectual property protection and increased chance of licensing.  We also include 
forward citations up to 2011; highly-cited patents have been used to measure important 
technologies in bio-medical innovation (Gittelman and Kogut, 2003). In cases with multiple 
patents, we use the maximum forward to any single patent in the case.  To account for age bias 
on citations, we calculate this variable as “forward cites per year” which is cumulative forward 
citations divided by the number of years since grant date through 2011. Number of inventors on 
case – This variable measures the number of unique inventors listed on a case.  Inventions with 
more inventors may signal more effort and costs involved in a project (Gittelman and Kogut, 
2003; Subramanian et al, 2013), and larger-scale projects may be more likely to be licensed.  
Large-scale projects are also more likely to include inventors with diverse research backgrounds 
who have links to potential licensors, so it’s important to net out that effect when estimating the 
relationship between team composition and the probability of licensing.  Number of Patents per 
case - A higher number of patents could signify important inventions with a higher probability of 
licensing. 
MGH – A dummy variable that indicates whether the invention was made at the Mass 
General (1) or Brigham and Womens’ Hospita (0)l. 
Year – We control for time with variables that indicate whether the invention was 
disclosed in the 1980s or 1990s; the 2000s (when there are far fewer inventions due to right 
truncation) is the omitted category.  
6. Proportional hazard models of licensing  
We estimate a semi-parametric proportional hazard model, the Cox Hazard Model, in 
which time to first license is the dependent variable. The model is semi-parametric because it 
estimates a baseline non-parametric hazard function from the data, without assuming a specific 
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underlying distribution. 18  The covariates enter the model linearly, i.e. they modify the hazard 
function multiplicatively, giving it the name proportional. In the Cox Hazard model estimation 
formula below, h(t|xj) is the hazard of licensing computed by using the baseline hazard ℎ0 (𝑡) 
estimated from the data without distributional assumptions and modified proportionally by the 
vector of independent variable coefficients -  bx.  
h(t|xj) = ℎ0 (𝑡)𝑒
𝑏𝑥 𝑥𝑗 
6a. Models of specialized and cross-domain inventions 
Model 1 includes the controls and fixed effects for technology class as well as the 
scientific specialization of the researchers on the patents.   The effect of scientific stars is not 
significant; however, the effect of lead inventor experience in prior patenting is significant 
(p<.01), indicating the scientists’ “taste” for invention and their success in patenting is predictive 
of successful licensing.  Several of the controls for patent importance are also significant, 
indicating a correlation (rather than a causal relationship) between many bibliometric measures 
and the ex-post success of a patent (Gittelman, 2008).  Forward citations and number of patents 
on a case (which correlate with technological importance) are both positive and significant 
(p<.001) but the number of inventors on a case is not significant.    
In Model 2 we include a dummy variable that distinguishes between stars who are 
clinicians and others (mostly PhDs).  It is positive and significant (p<0.1), and the main effect of 
star is now negative.   This result suggests that stars engaged in clinical research are associated 
with licensed inventions, but those in basic science are not.   However, our measure on clinical 
stars does not remain significant in models that follow which overlap on the clinical research 
                                                          
18 Our results are robust to alternative hazard models with distributional assumptions (Weibull and Log-Normal) as 
well as to alternative hazard specifications such as Accelerated Failure Time (AFT). 
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dimension; we note however that the impact of highly cited scientists on innovation does appear 
sensitive to whether scientists are clinicians or Phds.  
In Model 3 and 4 we explore the idea that inventions associated with clinical researchers 
are more likely to be licensed than those associated with PhDs.  In Model 3 we first estimate the 
hazard of licensing of  inventions composed only of MDs (Single Domain Clinical) against the 
omitted category of all other invention types combined, and find that these teams do have a 
higher hazard of licensing (p<0.01).  Model 4 shows that, conversely, inventions composed only 
of PhDs have a lower hazard of licensing compared to all others (p<0.01). Taken together, the 
results provide strong support for our proposition that inventions associated with clinical 
research are more likely to be licensed than inventions by PhDs.  It is important to underscore 
that these effects control for the technology of the invention, as well as the departmental 
specialization of the researchers. 
There are many teams that are distributed, including those that mix both MDs and PhDs 
or include at least one inventor with an MD-PhD.  We estimate how these combinations affect 
the hazard of licensing.  Model 5 estimates the effects of cross-domain teams of both types: 
inventions on which MDs and PhDs collaborate (Distributed) and inventions that include an 
individual with MD-PhD (Integrated).  The Single Domain inventions are the omitted categories.    
These models show there is no difference in the hazard of licensing between the cross-domain 
inventions and the single-domain inventions; integration of basic and clinical research alone does 
not increase the hazard of licensing as compared to inventions by single domain teams. The 
results do not supportthe common wisdom that integrated teams perform better than single 
domain teams. 
  In Model 6, we further probe the effect of integrating clinical and basic knowledge on 
inventions; the omitted category is inventions with all PhDs.  Therefore, the remaining 
inventions all have at least one clinician, and have some combination of MD, MD-PhD, and 
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PhD.  Again, we find that teams with only MDs are more likely to be licensed (p<0.01), 
however, teams that combine MDs and PhDs or have MD-PhDs have a higher hazard of 
licensing  but the results are not statistically significant.  These results contradict the premise of 
the translational model that combining basic and clinical research will be associated with greater 
innovation performance.   
In model 7 we explore the effect of team leaders on licensing.   These models capture our 
proposed “paradigm effect” insofar as the lead scientist determines the overall orientation of the 
research that led to the invention (Bercovitz and Feldman, 2011). If our proposition that these are 
different logics of research is correct, the lead inventor should matter to outcomes even after 
controlling for the team type, type of technology and the scientific specialization of the scientists. 
In Model 7 we control for team type by including variables that indicate whether the team 
included both MDs and PhDs (as we did in Model 5).  We include dummy variables for 
inventions with MD leaders or MD-PhD leaders as compared to the omitted category of PhD 
leaders;  we find that the latter is at a significantly lower hazard of licensing than teams with MD 
or MD-PhD leaders (p<0.05).  This lends further support that the clinical research paradigm, as 
expressed by the team leader, increases the hazard of licensing.   
7.  Discussion and conclusion 
This paper addresses an important gap in our knowledge about the relative contributions 
of basic and clinical research in medical innovation.  We consider clinical research as a research 
paradigm distinct from basic science, which is unique in affording interactions with afflicted 
patients as part of the research process by scientists trained in both medicine and research.  We 
contrast this with basic science, typically performed in a lab, which is engaged with 
understanding fundamental cause-effect relationships using reductionist, abstract models.  
Historically, most medical discoveries were made at the bedside; however, recent advances in 
knowledge about molecular biology as well as vastly powerful information-processing tools have 
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transformed the model of medical research.  A new paradigm has emerged, in which large-scale 
data, teams, and basic research play a more central role than in the past. 
Despite these shifts, the rate of medical innovation has not witnessed the expected boost 
in productivity (LeFanu, 2012).  Current policy has diagnosed the problem as one of failure to 
translate basic research findings to clinical settings, and new institutions and policies have been 
designed to build bridges between the “bench” and the “bedside”, for instance by encouraging 
cross-disciplinary teams.  We propose that given the complexity of many medical problems, 
basic research has limited direct utility to technological innovation; instead, we propose that the 
clinical paradigm remains important in medical discovery because its search logic is embedded 
in the complex and variable context in which disturbances occur: the human body. 
Our results provide support for the proposition that research by clinicians remains an 
important element in medical discovery.  We find a pronounced “clinician effect”: inventions by 
teams of clinicians are more likely to be licensed by firms, whereas inventions by basic 
researchers have a lower chance of being licensed.  Moreover, collaborations between clinicians 
and PhDs do not add to the hazard of licensing.  We found this result surprising, as we expected 
a positive impact of combining both domains of knowledge.  The only case in which basic 
research increases the probability of licensing is when it is embodied in a team leader who spans 
both clinical and basic science (MD-PhD).     
Our findings are intriguing, given that our context consists of two major Academic 
Medical Centers which are dedicated to the integration of clinical and basic research.  We find 
that the distinctions between clinical and basic research matter, even in an institutional 
environment where the distinctions between them should be less pronounced than they would 
between (for instance) universities and medical schools, or universities and firms.    In an AMC 
we expect that PhD scientists would have a greater-than-average “taste” for clinically applicable 
research than their counterparts in university laboratories, and that MDs would have a greater 
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than average “taste” for basic research than their practitioner counterparts.  In other words, we 
expect that both PhDs and MDs in Academic Medical Centers are “Pasteur scientists” – 
conducting scientific research but with an eye to practical utility. Our data on technological 
fields bears this out, revealing PhD scientists invent in what would be considered “applied” 
fields (e.g. surgery and devices) and MDs invent in basic science fields (molecular biology).  
Despite the expectation that they would be similarly oriented and work on similar problems, and 
controlling for field and specializations, we nonetheless find a difference in the commercial 
potential of their projects.  We interpret these differences as evidence that researchers in the 
clinical and basic research domains are driven by different logics of search, and those paradigms 
matter for the commercial potential of their inventions.   Our findings that teams led by clinicians 
perform better than those led by PhDs – even controlling for whether they are mixed teams – 
gives more support to our claim that research paradigms, and not just scientific specializations, 
are important drivers of inventive success. 
It might be argued that the fruits of basic research take years to translate to a market and 
that more time is needed for their value to be observed.  This argument can be countered on three 
levels.  First, these inventions are patented inventions so have been deemed to have practical 
utility by the Technology License Office and the USPTO.  They span a range of technologies, 
rather than a few patent classes that might be considered “basic” (e.g. molecular biology).  Our 
time period spans some thirty years, and our results show that the differences are robust over the 
time period.19  Finally, the characterization of basic research as “early stage” implies an 
evolution from bench to bedside that is inaccurate in terms of the process by which medical 
innovations are discovered (Gelijns et al, 2001).   As our results highlight, despite the close links 
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to science, applied research methods have formed a fruitful starting point for discovery and 
commercial development (Nelson, 2003).   
Our findings help shed light on prior empirical research on boundary spanners as well as 
star scientists, and their differential contributions to innovation.  As discussed earlier, it remains 
ambiguous whether the prior findings of a positive (negative) relationship between boundary 
spanners (stars) and technological innovation stem from differences across basic and applied 
scientific fields.  Our findings suggest that these effects may, in fact, matter:  academic stars only 
have a positive impact on innovation when they are clinicians, suggesting that the negative 
relationship found in prior work could reflect a proxy for basic research.   Regarding boundary 
spanners, we propose that the “Clinician effect” in our data supports the idea that boundary 
spanners matter to innovation because they are more likely to be engaged in applied science and 
engage in technological learning, not the more general case of joint activities of scientific 
research and invention.  Indeed, insofar as both MDs and PhDs in Academic Medical Centers 
may both be considered boundary spanners, we show that only one group of boundary spanners 
increases the rate of licensing.  We propose that, taken together, our results help to unpack this 
important source of unobserved heterogeneity across inventing scientists, a topic that is now 
emerging as an important stream of research in its own right (e.g. Sauermann and Roach, 2014; 
Sauermann and Stephan, 2013).  We leave to future research to further investigate these 
distinctions across groups of scientists who contribute both to research and to technological 
innovations.  
 Our findings have implications for the growing importance of teams and “big data” in 
science that necessitate specialized resources and skills to gather and analyze (Jones, 2009; 
Wuchty et al, 2007).   We conceptualize basic and clinical research domains as not just different 
types of knowledge but distinct paradigms of research, and find that clinical research, which has 
historically been the key locus of medical innovation, continues to be important, even in a period 
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of burgeoning basic research and data-analytical frameworks in the life sciences.  Our results 
show that the lead inventor has an additional effect over and above team composition on the 
success of the invention.  We interpret our results to mean that scientists are not just bits of 
specialized knowledge and skills that may be combined and changed as the task requires; they 
are committed to specific professional identities and scientific paradigms that shape the questions 
they ask, the data and methods they employ to address them, and whether they adhere to a 
predictive or learning-in-practice logic of search.  Our results question the idea, central in the 
translational model, that a more intensive application of basic science to innovation is needed to 
spur innovation, and that clinical researchers should partner with basic research.  Instead, we find 
that the clinical research paradigm remains important in the development of useful new 
treatments and health-enabling technologies.  
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Table 1: Estimates of the Hazard of Licensing, Cox Hazard Model    
   
VARIABLES Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 
Single Domain 
Clinical    0.515***   0.756***  
   (0.193)   (0.255)  
Single Domain 
Research    -0.544**    
    (0.230)    
Cross Domain 
Integrated     -0.0570 0.396 -0.415 
     (0.206) (0.263) (0.325) 
Cross Domain 
Distributed     -0.0977 0.321 -0.146 
     (0.244) (0.291) (0.249) 
Lead MD       0.482** 
 
      (0.207) 
Lead MD-PhD       0.752** 
 
      (0.350) 
Lead Other       0.504 
       (0.660) 
Clinician Star 
Scientist  0.912* 0.710 0.624 0.882* 0.569 0.724 
  (0.484) (0.497) (0.501) (0.492) (0.506) (0.504) 
Star Scientist on 
Team 0.0790 -0.619 -0.503 -0.346 -0.581 -0.367 -0.515 
 (0.245) (0.455) (0.461) (0.475) (0.462) (0.473) (0.471) 
Lead Inventor 
Experience 0.0503*** 0.0511*** 0.0497*** 0.0524*** 0.0498*** 0.0502*** 0.0553*** 
 (0.0152) (0.0153) (0.0151) (0.0153) (0.0154) (0.0153) (0.0158) 
Forward Cites per 
Year 1.122*** 1.069*** 1.062*** 1.032*** 1.070*** 1.051*** 1.008*** 
 (0.282) (0.283) (0.284) (0.284) (0.285) (0.285) (0.289) 
Prior Art  -0.000327 0.000268 0.000921 0.000322 0.000308 0.000356 0.000442 
 (0.00565) (0.00565) (0.00573) (0.00572) (0.00578) (0.00588) (0.00586) 
Num Patents on Case 0.223*** 0.225*** 0.231*** 0.252*** 0.220*** 0.249*** 0.242*** 
 (0.0527) (0.0530) (0.0533) (0.0555) (0.0537) (0.0552) (0.0550) 
Num Inventors on 
Case 0.0366 0.0205 0.0922 0.0420 0.0606 0.0835 0.0933 
 (0.0918) (0.0926) (0.0956) (0.0936) (0.0979) (0.0980) (0.100) 
Single Inventor Case -0.0266 -0.0729 -0.0954 0.0634 -0.0545 -0.0200 -0.0307 
 (0.220) (0.221) (0.223) (0.227) (0.229) (0.229) (0.232) 
Device -0.181 -0.186 -0.200 -0.147 -0.142 -0.193 -0.223 
 (0.251) (0.250) (0.253) (0.253) (0.254) (0.254) (0.260) 
MGH -0.204 -0.116 -0.187 -0.164 -0.115 -0.208 -0.188 
 (0.182) (0.188) (0.190) (0.189) (0.189) (0.191) (0.192) 
Filed in 1980s 0.185 0.181 0.167 0.152 0.170 0.159 0.203 
 (0.281) (0.281) (0.283) (0.283) (0.283) (0.283) (0.285) 
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Filed in 1990s 0.206 0.219 0.179 0.166 0.194 0.168 0.193 
 (0.234) (0.235) (0.235) (0.237) (0.236) (0.236) (0.237) 
        
Technology Fixed 
Effects YES YES YES YES YES YES YES 
Department Fixed 
Effects YES YES YES YES YES YES YES 
        
Observations 491 491 486 486 486 486 483 
 
Table 2: Summary Statistics for Main 
Variables     
  
Num of 
Observations Mean Std. Dev. Min Max 
Invention Licensed 491 0.427699 0.49525 0 1 
Single Domain Clinical  486 0.253086 0.435228 0 1 
Single Domain Research 486 0.228395 0.420231 0 1 
Cross Domain Integrated 486 0.339506 0.47403 0 1 
Cross Domain Distributed 486 0.179012 0.383758 0 1 
Lead MD 488 0.42418 0.494725 0 1 
Lead PhD 488 0.329918 0.470666 0 1 
Lead MD-PhD 488 0.227459 0.419622 0 1 
Clinician Star Scientist 491 0.089613 0.285918 0 1 
Star Scientist on Team 491 0.12831 0.334775 0 1 
Lead Inventor Experience 491 5.162933 5.053785 1 28 
Forward Cites per Year 491 0.382885 0.336362 0 2.5 
Prior Art  491 9.370672 13.31522 0 142 
Num Patents on Case 491 1.356415 0.933096 1 12 
Num Inventors on Case 491 2.183299 1.163653 1 9 
Single Inventor Case 491 0.311609 0.463623 0 1 
Device 491 0.219959 0.414641 0 1 
MGH 491 0.600815 0.49023 0 1 
Filed before 1990 491 0.230143 0.421353 0 1 
Filed in 1990s 491 0.576375 0.494636 0 1 
Technology Class: 
Molecular Biology 491 0.199593 0.400102 0 1 
Technology Class: Drug 491 0.348269 0.476908 0 1 
Technology Class: 
Chemistry 491 0.083503 0.276923 0 1 
Technology Class: Surgery 491 0.224033 0.417369 0 1 
Technology Class: Imaging 491 0.069246 0.254132 0 1 
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